Irisin Pretreatment Reveals Enhanced Protective Response Upon Hematopoietic Reconstitution in the Acquired Aplastic Anemia Mouse Model
The FASEB Journal · 15.07.2026 · 40 (13)
DOI: 10.1096/fj.202504816r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 27.06.2026. Verfasst von Hui Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Cheeloo College of Medicine, The Second Qilu Hospital, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Anemia, Aplastic, Fibronectins, Hematopoiesis. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Shandong Provincial Natural Science Foundation, MOST | National Natural Science Foundation of China (NSFC), SDU-KI Collaborative Research Project at Qilu Medical College.
Abstract (Originalsprache)
Acquired aplastic anemia (AA) is a prevalent nonmalignant hematologic disorder characterized by primary bone marrow failure (BMF), ineffective hematopoiesis, and consequent pancytopenia associated with abnormal immune responses and autoreactive T lymphocyte‐mediated dysfunction of hematopoietic stem and progenitor cells (HSPCs). Recently, we observed a remarkable decrease in serum irisin levels in patients with AA, as well as beneficial effects of irisin administration on HSPC stemness and pancytopenia‐related dysimmunity during BMF; however, the optimal protective effect of irisin on AA remains unknown. For this purpose, we further dissected the potential relationship between low irisin concentration and key T‐cell subsets in patients and systematically compared the therapeutic effects of irisin pretreatment and irisin treatment in an AA mouse model using multifaceted analyses (e.g., body condition, peripheral blood cell counts, conventional staining, inflammatory cytokine detection, cell viability analysis of HSPCs, and T‐cell subset analysis). Consistent with the decline in irisin concentration in AA, we further verified correlations with the indicated T‐cell subsets. Using our well‐established disease model, we found that AA mice with irisin pretreatment (Days −1 to 27) showed enhanced protective effects over those with irisin treatment (Days 7–27), including improved body condition and peripheral blood cell counts, reduced proinflammatory cytokines, rescue of HSPC stemness, and pancytopenia‐related T‐cell imbalance. Collectively, our data indicated the superiority of irisin pretreatment in alleviating AA‐associated autoreactive T lymphocyte‐mediated HSPC dysfunction and pancytopenia. Our findings provide new insights for the development of novel irisin‐based regimens with enhanced protective effects against AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Cheeloo College of Medicine, The Second Qilu Hospital, Shandong University, Jinan, China.
- Institute of Biotherapy for Hematological Malignancies, Shandong University, Jinan, China.
- Shandong University-Karolinska Institute Collaborative Laboratory for Stem Cell Research, Shandong University, Jinan, China.
- Department of Respiratory Intervention, Children's Hospital Affiliated to Shandong University, Jinan, China.
- Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China.
- Shandong Pharmaceutical Academy, Shandong Provincial Key Laboratory of Chemical Drugs, Jinan, China.
ORCID-Profile: Hui Li, Yang Jiang, Leisheng Zhang, Chengyun Zheng
Förderung
- Shandong Provincial Natural Science Foundation
- MOST | National Natural Science Foundation of China (NSFC)
- SDU-KI Collaborative Research Project at Qilu Medical College
- Taishan Scholar Special Funding of Shandong Province
- The Senior Medical and Healthcare Talent Visiting Program of Shandong Province
- Science and Technology Development Plan of Jinan Municipal Health Commission
- Natural Science Foundation of Jiangxi Province (Jiangxi Natural Science Foundation)
- Medical and Health Technology Project of Shandong Province
Zitieren
APA
Li, H., Kong, D., Liu, X., Li, X., Zhao, Y., Wang, Y., Li, S., Hu, J., Chen, Y., Jiang, Y., Wang, F., Han, Y., Shan, N., Xu, D., Tang, D., Zhang, L., & Zheng, C. (2026). Irisin Pretreatment Reveals Enhanced Protective Response Upon Hematopoietic Reconstitution in the Acquired Aplastic Anemia Mouse Model. The FASEB Journal, 40(13). https://doi.org/10.1096/fj.202504816r
Vancouver
Li H, Kong D, Liu X, Li X, Zhao Y, Wang Y, et al. Irisin Pretreatment Reveals Enhanced Protective Response Upon Hematopoietic Reconstitution in the Acquired Aplastic Anemia Mouse Model. The FASEB Journal. 2026;40(13). doi:10.1096/fj.202504816r
BibTeX
@article{Li2026,
author = {Li, Hui and Kong, Dexiao and Liu, Xia and Li, Xiaoyan and Zhao, Yi and Wang, Yongjing and Li, Shengli and Hu, Jianting and Chen, Yuan and Jiang, Yang and Wang, Fang and Han, Ying and Shan, Ningning and Xu, Dawei and Tang, Dongqi and Zhang, Leisheng and Zheng, Chengyun},
title = {Irisin Pretreatment Reveals Enhanced Protective Response Upon Hematopoietic Reconstitution in the Acquired Aplastic Anemia Mouse Model},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {13},
doi = {10.1096/fj.202504816r}
}
EUVIMED